Tags:AlternativeBioTechDevelopmentDrugHumanITProductPublicResearchTools
Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
Location: Belgium, East Flanders, Ghent
Total raised: $111.17397M
Founded date: 2001

Investors 4

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
28.02.2013-$41.188908...-gildehealt...
15.03.2010-$68.357372...-gildehealt...
19.02.2010Grant$1.62769M-gildehealt...

Mentions in press and media 14

DateTitleDescriptionCategoryAuthorSource
12.03.2020Precision ...Pathogens, as is clear to anyo...--agfunderne...
16.11.2018With ra­di...In­ter­est in tar­get­ed ra­di...FinancingEndpoints ...endpts.com...
25.10.2017Term Sheet...5 Qs WITH A DEALMAKER Vijay P...--fortune.co...
18.10.2017Term Sheet...5 Qs WITH A DEALMAKER Good mo...--fortune.co...
03.10.2017Ablynx fil...Ablynx has moved quickly to ca...Biotech-fiercebiot...
03.10.2017Term Sheet...DIRTY DEALINGS Good morning, ...--fortune.co...
28.02.2013Ablynx Suc...REGULATED INFORMATION GHENT, ...--gildehealt...
01.10.2010Ablynx sta...GHENT, Belgium - Ablynx [Euron...--gildehealt...
15.03.2010Ablynx suc...GHENT, Belgium - Ablynx, the b...--gildehealt...
19.02.2010ABLYNX Rec...GHENT, Belgium - Ablynx [Euron...--gildehealt...
Show more